Overview

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

Status:
Active, not recruiting

Trial end date:
2022-05-20

Target enrollment:

Participant gender:

Summary

The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who are on a stable background of methotrexate (MTX and who have an inadequate response to MTX.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Adalimumab
Methotrexate
Upadacitinib